CN113413458A - 一种具有延缓衰老作用的药物组合物及其制备方法 - Google Patents
一种具有延缓衰老作用的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN113413458A CN113413458A CN202110676737.5A CN202110676737A CN113413458A CN 113413458 A CN113413458 A CN 113413458A CN 202110676737 A CN202110676737 A CN 202110676737A CN 113413458 A CN113413458 A CN 113413458A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- grape
- mannatide
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000003712 anti-aging effect Effects 0.000 title claims description 13
- 241000219095 Vitis Species 0.000 claims abstract description 46
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 46
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 46
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 46
- 108010010998 polyactin A Proteins 0.000 claims abstract description 23
- 239000011324 bead Substances 0.000 claims abstract description 22
- 239000003292 glue Substances 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 15
- 235000008524 evening primrose extract Nutrition 0.000 claims abstract description 13
- 229940089020 evening primrose oil Drugs 0.000 claims abstract description 13
- 239000010475 evening primrose oil Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 241001550206 Colla Species 0.000 claims description 5
- 241000209020 Cornus Species 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 230000009758 senescence Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 230000032683 aging Effects 0.000 abstract description 11
- 210000003056 antler Anatomy 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241001018563 Nekemias grossedentata Species 0.000 description 2
- 241000219925 Oenothera Species 0.000 description 2
- 235000004496 Oenothera biennis Nutrition 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000021688 musculoskeletal movement Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
Abstract
本发明公开了一种具有延缓衰老作用的药物组合物，涉及医药技术领域。包括以下重量份的原料：月见草油10‑20份，葡萄叶12‑16份，葡萄皮8‑15份，活珠子冻干粉6‑8份，鹿角胶3‑5份，甘露聚糖肽6‑12份。本发明制备简单，以月见草油、葡萄叶、葡萄皮、活珠子冻干粉、鹿角胶和甘露聚糖肽为主，辅以其他药物成分，具有抗氧化、增强免疫力等的功效，使用安全，无任何毒副作用，能对衰老的根源予以干预。
Description
技术领域
本发明涉及医药技术领域，具体涉及一种具有延缓衰老作用的药物组合物及其制备方法。
背景技术
衰老是人类生命发展过程中必经的一个过程，其主要的生理表现如下：
(1)形态变化。包括：①细胞变化。主要表现为细胞数的逐步减少。②组织与器官的变化。由于内脏器官和组织的细胞数量减少，从而发生萎缩、重量减轻。③整体变化。随着年龄的增长，体形和外形出现变化，如头发变白；皮肤弹性降低，出现皱纹，出现老年斑；牙齿松动脱落，耳聋、眼花、驼背，身高逐渐缩短等。
(2)生理功能减退。包括：①心血管系统功能的衰退。如心肌纤维逐渐萎缩，心肌细胞内老年色素(脂褐质)沉积，心瓣膜变得肥厚硬化、弹性降低等。②呼吸器官老化。表现为肺容量降低，呼吸功能明显减退，代偿能力降低。③消化系统的变化。主要是口腔、胃肠功能减弱，牙龈、牙齿发生萎缩性变化。④肌肉骨骼运动系统变化。主要表现在随年龄增长，肌纤维变细、弹性降低、收缩力减弱；骨骼中有机成份减少，无机盐增多，因而致使骨的弹性的韧性降低，易骨折等。⑤神经系统变化。主要表现为脑细胞的某种程度的丧失；神经传导速度降低；老年人的动作迟缓，反映灵活性减弱等。
(3)主要感觉器官功能减退。如视觉、听觉、嗅觉、味觉、皮肤感觉(包括触觉、温觉、痛觉)能力减退。此外，老年人心理运动反应也相应迟缓。
由于衰老给身体健康造成了极大的影响，因此，追求年轻化已经成为各行各类人所追求向往的目标。
然而，现在的抗衰老产品，比如玻尿酸等都只是从局部入手，哪里出现问题在哪里修补，属于“头痛医头、脚痛医脚”的治标不治本的方法，缺乏一种从整体调理机体功能入手，对衰老的根源予以干预的医疗制剂，且目前该类产品主要采用注射方式的进行，操作不便，且会导致患者疼痛。
发明内容
本发明提供的一种具有延缓衰老作用的药物组合物及其制备方法，旨在解决上述背景技术中存在的问题。
为了实现上述技术目的，本发明主要采用以下技术方案：
一种具有延缓衰老作用的药物组合物，包括以下重量份的原料：月见草油10-20份，葡萄叶12-16份，葡萄皮8-15份，活珠子冻干粉6-8份，鹿角胶3-5份，甘露聚糖肽6-12份。
上述药物组合物中，优选的，包括以下重量份的原料：月见草油15份，葡萄叶14份，葡萄皮12份，活珠子冻干粉7份，鹿角胶4份，甘露聚糖肽9份。
本发明的主要配方原料为月见草油、葡萄叶、葡萄皮、活珠子冻干粉、鹿角胶和甘露聚糖肽，各原料药功效如下：
月见草：原名晚樱草，主要成分：γ-亚麻油酸，镁，锌，铜、维生素C、E、B6、B5，可以调合基础油和精油的油脂，具有多项治疗、美白功能，制成胶囊内服可以治疗心血管疾病，经前症候群，更年期综合症。
葡萄叶、葡萄皮：葡萄叶中黄酮含量非常丰富，其主体物质为二氢杨梅素，它对自由基的清除率高达73.3％～91.5％，可减轻机体内氧化损伤，具有抗衰老的作用。藤茶还能减轻动物肝组织的变性和坏死程度，有保肝护肝之作用。藤茶还具有防止动脉粥样硬化以及降血脂、降血糖等作用。另外，葡萄叶经过杀青、揉捻、烘干而成的类茶制品称为藤茶，藤茶中不含鞣酸，不会影响蛋白质的消化和吸收，不会夺取体内作为造血原料的铁质；也不含有咖啡因一类具有兴奋作用的化合物，故对于贫血、睡眠质量不高又喜欢饮茶的人，可以是一种理想的替代品。而葡萄皮中含有比葡萄肉和葡萄籽中更丰富的白藜芦醇，这是一种多羟基酚类化合物，这种物质除能预防心脑血管疾病外，还具有很强的抗癌能力。
活珠子冻干粉：“活珠子”富含游氨基酸和多种生物激素，特别是胚胎液，富含活性生态营养元素，极易为人体所吸收。经常食用“活珠子”，能显著改善因气血虚亏所引起的多种症状，增强人体免疫力和抵抗力，滋补养颜，保健强身。
鹿角胶：鹿角胶主要以鹿角为原材料进行加工熬制而成，《神农草本经》将其列为上品，名"白胶"，又名"鹿胶"，味甘、平，无毒，入肝、肾经。具有壮元阳、补气血、生精髓、暖筋骨的作用。治疗各种虚损、劳伤，用途之广不亚于鹿茸。
甘露聚糖肽：化学性质稳定且具有一定均一性的混合物，不存在单糖、双糖等小分子糖类和游离氨基酸，完全由不同链长的甘露聚糖肽分子构成，分子质量约为71ku。甘露聚糖肽中总糖的含量为87.7％～90.3％，主要为甘露糖以及少量的葡萄糖残基；氨基酸总含量为4.5％～ 6.2％，主要为天门冬氨酸、苏氨酸、丝氨酸、谷氨酸、丙氨酸和亮氨酸，其中糖链与肽链的连接有N—糖苷键连接和O—糖苷键连接两种方式，具有改善和增强机体免疫功能和应激能力的作用。
本发明的药物组合物是以月见草油、葡萄叶、葡萄皮、活珠子冻干粉、鹿角胶与甘露聚糖肽为原料药，加入药学上可接受的辅料，按照常规方法制成临床上可以接受的、药剂学中所说的常规内服制剂。
优选的，所述剂型为片剂、胶囊剂、丸剂、颗粒剂。
本发明的药物组合物可制成胶囊剂，也可以加入相应辅料制成片剂、丸剂、颗粒剂等。制备不同剂型仅所用的辅料不同，药物有效成分还是一样的，治疗效果也相同或近似。片剂的辅料为淀粉、微晶纤维素、预胶化淀粉、乳糖、羧甲淀粉钠、超级羧甲淀粉钠、低取代羟丙基纤维素、羟丙甲纤维素、滑石粉、硬脂酸镁；丸剂的辅料为淀粉、微晶纤维素、羧甲淀粉钠、羟丙甲纤维素；颗粒剂的辅料为庶糖粉、糊精；胶囊剂的辅料为淀粉、预胶化淀粉、微晶纤维素、羧甲淀粉钠、超级羧甲淀粉钠、羟丙甲纤维素、滑石粉、二氧化硅、硬脂酸镁。
本发明还提供了上述具有延缓衰老作用的药物组合物的制备方法，包括如下步骤：
(1)将葡萄叶、葡萄皮洗净、晒干后粉碎，然后用水煎煮2次，合并滤液；
(2)将滤液浓缩呈60-80℃条件下，相对密度为1.05-1.32的清膏或稠膏；
(3)将清膏、月见草油、活珠子冻干粉、鹿角胶和甘露聚糖肽与药用量的辅料混合，制成所需剂型的药物组合物。
本发明所述的具有延缓衰老作用的药物组合物在制备延缓衰老药物或保健品中的应用。
与现有技术相比，本发明具有以下有益效果：本发明制备简单，以月见草油、葡萄叶、葡萄皮、活珠子冻干粉、鹿角胶和甘露聚糖肽为主，辅以其他药物成分，具有抗氧化、增强免疫力等的功效，使用安全，无任何毒副作用，能对衰老的根源予以干预。
具体实施方式
以下对本发明的具体实施方式进行详细说明。应当理解的是，此处所描述的具体实施方式仅用于说明和解释本发明，并不用于限制本发明。
实施例1
取月见草油10份，葡萄叶12份，葡萄皮8份，活珠子冻干粉6份，鹿角胶3份，甘露聚糖肽6份。
(1)将葡萄叶、葡萄皮洗净、晒干后粉碎，然后用水煎煮2次，合并滤液；
(2)将滤液浓缩呈60-80℃条件下，相对密度为1.05-1.32的清膏或稠膏；
(3)将清膏、月见草油、活珠子冻干粉、鹿角胶和甘露聚糖肽与药用量的辅料混合，制粒，干燥，加入1％的硬脂酸镁，混匀，装胶囊，即得，每粒装0.5g。
实施例2
取月见草油15份，葡萄叶14份，葡萄皮12份，活珠子冻干粉7份，鹿角胶4份，甘露聚糖肽9份。
(1)将葡萄叶、葡萄皮洗净、晒干后粉碎，然后用水煎煮2次，合并滤液；
(2)将滤液浓缩呈60-80℃条件下，相对密度为1.05-1.32的清膏或稠膏；
(3)将清膏、月见草油、活珠子冻干粉、鹿角胶和甘露聚糖肽与药用量的辅料混合，制粒，干燥，加入1％的硬脂酸镁，混匀，装胶囊，即得，每粒装0.5g。
实施例3
取月见草油20份，葡萄叶16份，葡萄皮15份，活珠子冻干粉8份，鹿角胶5份，甘露聚糖肽12份。
(1)将葡萄叶、葡萄皮洗净、晒干后粉碎，然后用水煎煮2次，合并滤液；
(2)将滤液浓缩呈60-80℃条件下，相对密度为1.05-1.32的清膏或稠膏；
(3)将清膏、月见草油、活珠子冻干粉、鹿角胶和甘露聚糖肽与药用量的辅料混合，制粒，干燥，加入1％的硬脂酸镁，混匀，装胶囊，即得，每粒装0.5g。
除了上述实施例中的组合物外，本领域技术人员还可以根据上述描述得到其他原料组成的配方，上述实施例并非对本发明内容进行限制。另外，除了按照常规方法将组合物制成胶囊剂外，还可以根据现有技术中公开的常规方法将本发明组合物制成片剂、丸剂、颗粒剂。
实施例4抗衰老的实验
从内科门诊选择病例，其中，实施例1-3的患者各100例，在病史、病情、年纪和性别上均无明显差异性，年龄在60～78之间，病程半年以上，停服一切药物，观察期为半年，除进行日常饮食外，增加使用本发明实施例1-3的胶囊，并作结果统计，结果如下：
表1：对比例与本实施例1-3的抗衰老实验结果
从以上表1中，可以得知，本发明能有效改善老年化的相关症状，表面本发明的药物组合物具有明显的延缓衰老的效果。
以上详细描述了本发明的优选实施方式，但是，本发明并不限于上述实施方式中的具体细节，在本发明的技术构思范围内，可以对本发明的技术方案进行多种简单变型，这些简单变型均属于本发明的保护范围。
Claims (6)
1.一种具有延缓衰老作用的药物组合物，其特征在于，包括以下重量份的原料：月见草油10-20份，葡萄叶12-16份，葡萄皮8-15份，活珠子冻干粉6-8份，鹿角胶3-5份，甘露聚糖肽6-12份。
2.根据权利要求1所述的具有延缓衰老作用的药物组合物，其特征在于：包括以下重量份的原料：月见草油15份，葡萄叶14份，葡萄皮12份，活珠子冻干粉7份，鹿角胶4份，甘露聚糖肽9份。
3.根据权利要求1或2任一项所述的具有延缓衰老作用的药物组合物，其特征在于：它是以月见草油、葡萄叶、葡萄皮、活珠子冻干粉、鹿角胶与甘露聚糖肽为原料药，加入药学上可接受的辅料，按照常规方法制成临床上可以接受的、药剂学中所说的常规内服制剂。
4.根据权利要求3所述的制备具有延缓衰老作用的药物组合物的方法，其特征在于：所述剂型为片剂、胶囊剂、丸剂、颗粒剂。
5.一种如权利要求1-4任一项所述的具有延缓衰老作用的药物组合物的制备方法，其特征在于，包括如下步骤：
(1)将葡萄叶、葡萄皮洗净、晒干后粉碎，然后用水煎煮2次，合并滤液；
(2)将滤液浓缩呈60-80℃条件下，相对密度为1.05-1.32的清膏或稠膏；
(3)将清膏、月见草油、活珠子冻干粉、鹿角胶和甘露聚糖肽与药用量的辅料混合，制成所需剂型的药物组合物。
6.一种权利要求1-4任一项所述的具有延缓衰老作用的药物组合物在制备延缓衰老药物或保健品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110676737.5A CN113413458A (zh) | 2021-06-18 | 2021-06-18 | 一种具有延缓衰老作用的药物组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110676737.5A CN113413458A (zh) | 2021-06-18 | 2021-06-18 | 一种具有延缓衰老作用的药物组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113413458A true CN113413458A (zh) | 2021-09-21 |
Family
ID=77789050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110676737.5A Pending CN113413458A (zh) | 2021-06-18 | 2021-06-18 | 一种具有延缓衰老作用的药物组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113413458A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927312A (zh) * | 2005-09-05 | 2007-03-14 | 郭爱华 | 一种含有葡萄提取物的药物组合物及其制备方法、用途 |
| CN105901738A (zh) * | 2016-06-14 | 2016-08-31 | 益倍（天津）生物科技有限公司 | 一种发酵葡萄提取物及其制备方法与含其制剂 |
| CN107625113A (zh) * | 2017-09-06 | 2018-01-26 | 贵州神奇药物研究院 | 一种提高免疫力、补充能量的含片及其制备方法 |
| CN107714769A (zh) * | 2017-10-27 | 2018-02-23 | 南京多宝生物科技有限公司 | 一种促进血液循环的月见草油胶丸及其制备方法 |
| CN108676061A (zh) * | 2018-05-23 | 2018-10-19 | 国药心制药有限公司 | 甘露聚糖肽及其纯化方法 |
| CN211521556U (zh) * | 2019-11-29 | 2020-09-18 | 西安医学院 | 一种用于制备甘露聚糖肽口服液的导流装置 |
-
2021
- 2021-06-18 CN CN202110676737.5A patent/CN113413458A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927312A (zh) * | 2005-09-05 | 2007-03-14 | 郭爱华 | 一种含有葡萄提取物的药物组合物及其制备方法、用途 |
| CN105901738A (zh) * | 2016-06-14 | 2016-08-31 | 益倍（天津）生物科技有限公司 | 一种发酵葡萄提取物及其制备方法与含其制剂 |
| CN107625113A (zh) * | 2017-09-06 | 2018-01-26 | 贵州神奇药物研究院 | 一种提高免疫力、补充能量的含片及其制备方法 |
| CN107714769A (zh) * | 2017-10-27 | 2018-02-23 | 南京多宝生物科技有限公司 | 一种促进血液循环的月见草油胶丸及其制备方法 |
| CN108676061A (zh) * | 2018-05-23 | 2018-10-19 | 国药心制药有限公司 | 甘露聚糖肽及其纯化方法 |
| CN211521556U (zh) * | 2019-11-29 | 2020-09-18 | 西安医学院 | 一种用于制备甘露聚糖肽口服液的导流装置 |
Non-Patent Citations (4)
| Title |
|---|
| 刘晓瑞，等: "月见草油抗衰老作用的实验研究", 《中国老年学杂志》 * |
| 李翠苹，等: "二氢杨梅素研究进展", 《化学试剂》 * |
| 贾德安，等: "白藜芦醇心血管保护作用机制的研究进展", 《高血压杂志》 * |
| 陈富军，等: "略述鹿角胶的临床应用及现代研究", 《光明中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102224891B (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
| EP3530277A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
| CN1742927A (zh) | 枸杞桑椹片及其制备工艺 | |
| CN111467481A (zh) | 一种改善和/或预防骨关节炎的组合物及其应用 | |
| CN1939520A (zh) | 一种可改善记忆的益智胶囊及其制备工艺 | |
| CN105124347A (zh) | 一种辣木降血糖组合物及其制备方法 | |
| CN106236927A (zh) | 一种具有增强免疫力和抗疲劳作用的中药组合物及其制备方法与用途 | |
| CN109170470A (zh) | 一种治疗糖尿病的固体饮料及其制备方法 | |
| KR20170121532A (ko) | 갱년기 증상 또는 골다공증 개선용 조성물 | |
| CN104352542A (zh) | 一种海参雪莲的组合物制剂及其制备方法 | |
| CN105029553A (zh) | 一种果汁蛋钙中药保健饮料及其制备方法 | |
| CN106690121A (zh) | 一种海参沙棘虫草硒制剂及其制备工艺 | |
| KR101910013B1 (ko) | 한약재 추출물（ｓｏｃｇ）을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
| CN115486541B (zh) | 一种具有美白功效的草本益生菌组合物及其制备方法 | |
| CN1401365A (zh) | 一种中药保健药物 | |
| CN113413458A (zh) | 一种具有延缓衰老作用的药物组合物及其制备方法 | |
| KR20080087941A (ko) | 저분자량 히알우론산을 함유하는 피부주름개선 및각질제거용 조성물 | |
| KR20050101143A (ko) | 글루코사민을 포함하는 퇴행성관절염 예방 및 개선을 위한조성물 및 그 제조방법 | |
| CN1313112C (zh) | 一种具有养神镇静作用的药物组合物 | |
| CN105101817A (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
| CN106924581A (zh) | 一种治疗腹痛的药酒及其制备方法 | |
| KR101528557B1 (ko) | 천년초 발효물 함유 의약 조성물 | |
| CN106177634A (zh) | 一种减肥瘦身复方制剂及其制备方法 | |
| CN1528182A (zh) | 一种保健食品及其制备方法 | |
| CN101669995A (zh) | 一种用于心脑血管疾病治疗和保健的组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210921 |
|
| RJ01 | Rejection of invention patent application after publication |